The following Life Sciences guidance note Produced in partnership with Eveline Van Keymeulen and Jeanne Fabre of Allen and Overy provides comprehensive and up to date legal information covering:
On 31 January 2020, the UK ceased to be an EU Member State and entered an implementation period during which it continues to be treated by the EU as a Member State for many purposes. As a third country, the UK can no longer participate in the EU’s political institutions, agencies, offices, bodies (except to the limited extent agreed), but it continues to be subject to EU law and must submit to the continuing jurisdiction of the Court of Justice of the EU in accordance with the transitional arrangements in Part 4 of the Withdrawal Agreement. For further reading, see: Brexit—Life Sciences and News Analysis: Brexit Bulletin—key updates, research tips and resources.
Pharmacovigilance is the process of collecting and understanding information relating to the adverse effects of medicinal product throughout their use in patients.
Before a medicinal product is authorised for use, information regarding its safety and efficacy is obtained from clinical trial.
However, it is essential that the safety of all medicinal products continues to be monitored throughout their use in patients because after authorisation they will typically be used in a larger number of patients, for a longer period of time and in combination with other medicinal products, meaning that adverse effects may occur that were not apparent during clinical trials.
EU law therefore requires marketing authorisation (MA) holders (MAHs), the European Medicines
**excludes LexisPSL Practice Compliance, Practice Management and Risk and Compliance. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Take a free trial
Take a free trial
0330 161 1234